Nuvectis Pharma (NVCT)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	35.44 mm	35.44 mm	35.44 mm	35.44 mm	35.44 mm	35.44 mm
Cash burn (monthly)	(no burn)	(no burn)	2.60 mm	2.20 mm	1.50 mm	1.21 mm
Cash used (since last report)	n/a	n/a	9.95 mm	8.43 mm	5.74 mm	4.63 mm
Cash remaining	n/a	n/a	25.49 mm	27.02 mm	29.71 mm	30.81 mm
Runway (months of cash)	n/a	n/a	9.8	12.3	19.8	25.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

NVCT institutional ownership history Ownership history

6.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	31	31	–
Opened positions	7	5	+40.0%
Closed positions	7	14	-50.0%
Increased positions	13	8	+62.5%
Reduced positions	8	12	-33.3%

13F shares	Current	Prev Q	Change
Total value	6.63 bn	5.97 bn	+11.0%
Total shares	1.55 mm	1.29 mm	+20.2%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Baldwin Brothers	355.96 k	$1.93 bn	+104.4%
Vanguard	325.30 k	$1.76 bn	+8.0%
Pontifax Management 4 G.P.	288.87 k	$2.28 mm	0.0%
Marshall Wace	124.57 k	$673.93 mm	+191.0%
Geode Capital Management	79.24 k	$428.78 mm	-0.6%
BLK BlackRock	62.34 k	$337.27 mm	+25.8%
Susquehanna International	45.61 k	$246.73 mm	+72.3%
Gsa Capital Partners	34.75 k	$188.00 k	-30.7%
Qube Research & Technologies	30.59 k	$165.51 mm	+36.4%
Millennium Management	29.70 k	$160.67 mm	-56.6%

Largest transactions	Shares	Bought/sold	Change
Baldwin Brothers	355.96 k	+181.83 k	+104.4%
Marshall Wace	124.57 k	+81.76 k	+191.0%
Iridian Asset Management	0.00	-55.38 k	EXIT
Millennium Management	29.70 k	-38.80 k	-56.6%
Oppenheimer & Co	25.00 k	+25.00 k	NEW
Vanguard	325.30 k	+24.16 k	+8.0%
Susquehanna International	45.61 k	+19.14 k	+72.3%
Squarepoint Ops	19.07 k	+19.07 k	NEW
Renaissance Technologies	0.00	-15.80 k	EXIT
Gsa Capital Partners	34.75 k	-15.38 k	-30.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

NVCT insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
6 Jan 26	Michael J. Carson	Common Stock	Grant	Acquire A	No	No	0	61,200	0.00	200,118
6 Jan 26	Enrique Poradosu	Common Stock	Grant	Acquire A	No	No	0	150,000	0.00	1,806,319
6 Jan 26	Shay Shemesh	Common Stock	Grant	Acquire A	No	No	0	150,000	0.00	1,793,068
6 Jan 26	Bentsur Ron	Common Stock	Grant	Acquire A	No	No	0	150,000	0.00	3,675,924
5 Nov 25	Juan Sanchez	Common Stock	Buy	Acquire P	No	No	5.79	13,000	75.27 k	78,150

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Nuvectis Pharma Initiated Phase 1b Study Of NXP900 In Combination With Astrazeneca's Tagrisso (Osimertinib) In Patients With EGFRmut+ NSCLC

17 Dec 25

NXP900 Phase 1b Clinical ProgramThe Phase 1b program was initiated with the NXP900 single agent (monotherapy) study following the successful completion of a Phase 1a dose escalation study in patients with advanced solid

Nuvectis Pharma,To Discuss Key NXP900 Preclinical And Clinical Data To Date And Strategy For Monotherapy And Combination Components Of NXP900 Phase 1b Clinical Program At Key Opinion Leader Meeting

25 Nov 25

Nuvectis Pharma, Inc. (NASDAQ:NVCT, the "Company"))), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need

Nuvectis Pharma Provides Highlights For NXP900 Poster Presentations For 2025 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics In Boston

27 Oct 25

Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,

Press releases

From Benzinga Pro

CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

4 Nov 25

FORT LEE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 4, 2025 at 07:30 ET by Nuvectis Pharma, Inc. (NASDAQ:NVCT), the tables were not included. The tables have been